Raisa S Pompe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6097756/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anesthetic Technique (Spinal vs. General Anesthesia) in Holmium Laser Enucleation of the Prostate: Retrospective Analysis of Procedural and Functional Outcomes among 1,159 Patients. Urologia Internationalis, 2023, 107, 336-343.	0.6	2
2	Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis. Cancers, 2022, 14, 740.	1.7	5
3	Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorganâ€confined prostate cancer. Prostate, 2022, 82, 949-956.	1.2	3
4	Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 161.e9-161.e14.	0.8	3
5	Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer. European Urology Oncology, 2021, 4, 817-820.	2.6	1
6	Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancer. World Journal of Urology, 2021, 39, 81-88.	1.2	11
7	Assessing the Outcome of Holmium Laser Enucleation of the Prostate by Age, Prostate Volume, and a History of Blood Thinning Agents: Report from a Single-Center Series of >1800 Consecutive Cases. Journal of Endourology, 2021, 35, 639-646.	1.1	20
8	The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature. European Urology Oncology, 2021, 4, 370-395.	2.6	25
9	Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 193-201.	2.0	7
10	Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study. European Urology Focus, 2020, 6, 1213-1219.	1.6	5
11	The Impact of Anxiety and Depression on Surgical and Functional Outcomes in Patients Who Underwent Radical Prostatectomy. European Urology Focus, 2020, 6, 1199-1204.	1.6	25
12	Tumor characteristics, oncological and functional outcomes after radical prostatectomy in very young men â‰ ‡ €‰45Âyears of age. World Journal of Urology, 2020, 38, 95-101.	1.2	8
13	Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 1.e11-1.e16.	0.8	3
14	Retrograde ejaculation after holmium laser enucleation of the prostate (HoLEP)—Impact on sexual function and evaluation of patient bother using validated questionnaires. Andrology, 2020, 8, 1779-1786.	1.9	13
15	Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages – Does extent of tumor involvement matter?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e1-637.e7.	0.8	1
16	Validation of the Social Security Administration Life Tables (2004–2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. European Urology Focus, 2019, 5, 807-814.	1.6	22
17	Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations. World Journal of Urology, 2019, 37, 469-479.	1.2	25
18	Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organâ€confined prostate cancer. Prostate, 2019, 79, 1832-1836.	1.2	38

RAISA S POMPE

#	Article	IF	CITATIONS
19	Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 575.e1-575.e7.	0.8	4
20	Impact of the estimated blood loss during radical prostatectomy on functional outcomes. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 298.e11-298.e17.	0.8	7
21	External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. European Urology, 2019, 75, 896-900.	0.9	74
22	Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. European Urology, 2019, 76, 106-114.	0.9	77
23	The Impact of Lymph Node Metastases Burden at Radical Prostatectomy. European Urology Focus, 2019, 5, 399-406.	1.6	19
24	Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions. European Urology Focus, 2019, 5, 545-549.	1.6	5
25	Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience. European Urology Focus, 2019, 5, 568-576.	1.6	5
26	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. Prostate, 2018, 78, 469-475.	1.2	40
27	Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. Prostate Cancer and Prostatic Diseases, 2018, 21, 386-393.	2.0	11
28	Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI. World Journal of Urology, 2018, 36, 705-712.	1.2	5
29	Survival benefit of local versus no local treatment for metastatic prostate cancer—Impact of baseline PSA and metastatic substages. Prostate, 2018, 78, 753-757.	1.2	27
30	Local treatment for metastatic prostate cancer: A systematic review. International Journal of Urology, 2018, 25, 390-403.	0.5	37
31	Longâ€ŧerm cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. Prostate, 2018, 78, 676-681.	1.2	23
32	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. Clinical Genitourinary Cancer, 2018, 16, 176-183.	0.9	16
33	Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged â‰\$0 years: a population-based study. Prostate Cancer and Prostatic Diseases, 2018, 21, 71-77.	2.0	13
34	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 81.e17-81.e24.	0.8	18
35	The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy. World Journal of Urology, 2018, 36, 1247-1253.	1.2	16
36	Does surgical delay for radical prostatectomy affect biochemical recurrence? A retrospective analysis from a Canadian cohort. World Journal of Urology, 2018, 36, 1-6.	1.2	20

RAISA S POMPE

#	Article	IF	CITATIONS
37	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. World Journal of Urology, 2018, 36, 7-13.	1.2	23
38	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. World Journal of Urology, 2018, 36, 51-57.	1.2	16
39	The impact of lymph node dissection and positive lymph nodes on cancerâ€specific mortality in contemporary <scp>pT</scp> _{2â€3} nonâ€metastatic renal cell carcinoma treated with radical nephrectomy. BJU International, 2018, 121, 383-392.	1.3	30
40	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, e141-e149.	0.9	10
41	First North American validation and headâ€toâ€head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. BJU International, 2018, 121, 592-599.	1.3	32
42	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. International Urology and Nephrology, 2018, 50, 71-78.	0.6	37
43	Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 527.e21-527.e28.	0.8	16
44	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. Experimental and Molecular Pathology, 2018, 105, 50-56.	0.9	6
45	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. European Urology Oncology, 2018, 1, 314-320.	2.6	19
46	The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. Canadian Urological Association Journal, 2018, 12, E325-30.	0.3	13
47	Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. European Urology Oncology, 2018, 1, 160-168.	2.6	15
48	Postoperative complications of contemporary open and robotâ€assisted laparoscopic radical prostatectomy using standardised reporting systems. BJU International, 2018, 122, 801-807.	1.3	52
49	External validation of the novel International Society of Urological Pathology (ISUP) Gleason grading groups in a large contemporary Canadian cohort. Canadian Urological Association Journal, 2018, 12, .	0.3	2
50	Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. Prostate, 2017, 77, 686-693.	1.2	33
51	Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline. Journal of Urology, 2017, 198, 354-361.	0.2	36
52	Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 243-249.	0.8	11
53	External Beam Radiotherapy Affects Serum Testosterone in Patients with Localized Prostate Cancer. Journal of Sexual Medicine, 2017, 14, 876-882.	0.3	16
54	Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment. World Journal of Urology, 2017, 35, 1833-1839.	1.2	17

RAISA S POMPE

#	Article	IF	CITATIONS
55	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1–2 N0 M0 renal cell carcinoma. World Journal of Urology, 2017, 35, 1899-1905.	1.2	28
56	Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center. European Urology Focus, 2017, 3, 615-620.	1.6	44
57	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. International Urology and Nephrology, 2017, 49, 2143-2149.	0.6	36
58	Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology, 2017, 71, 330-336.	0.9	57
59	Complications after salvage radical prostatectomy: vesicourethral anastomosis leaks and possible prevention. Translational Andrology and Urology, 2017, 6, 994-996.	0.6	1
60	Oncological, functional and perioperative outcomes in transplant patients after radical prostatectomy. World Journal of Urology, 2016, 34, 1101-1105.	1.2	10